胺碘酮与地高辛、利伐沙班及苯妥英的药物相互作用及联合用药策略:基于生理药代动力学模型的研究
本研究采用PBPK建模模拟胺碘酮与地高辛、利伐沙班或苯妥英联用时的药物相互作用。模拟显示,按说明书推荐剂量联用时,三种受变药的稳态暴露分别增加79%、38%和59%;将地高辛、利伐沙班和苯妥英剂量分别降低40%、25%和45%可达到与单药治疗相似的稳态浓度。
要点
- 胺碘酮联用地高辛时,地高辛稳态暴露增加79%,建议减少地高辛剂量40%。
- 胺碘酮联用利伐沙班时,利伐沙班稳态暴露增加38%,建议减少利伐沙班剂量25%。
- 胺碘酮联用苯妥英时,苯妥英稳态暴露增加59%,建议减少苯妥英剂量45%。
核心结论
- 成功构建了胺碘酮、利伐沙班和苯妥英的PBPK模型,可有效模拟胺碘酮与地高辛、利伐沙班或苯妥英联用时的药物相互作用。
- 基于模拟结果提出了联合用药时的剂量调整方案,为临床联合治疗提供指导。
研究设计与样本
- 采用PBPK建模方法,使用PK-Sim软件构建胺碘酮、利伐沙班和苯妥英模型,地高辛模型取自既往发表文献。
- 通过比较预测的血浆浓度-时间曲线和PK参数与既往发表健康受试者临床试验数据进行模型验证。
- 模拟药物相互作用场景以评估暴露水平,并根据暴露变化调整联合用药剂量方案。
主要发现
- 按说明书推荐剂量联用时,胺碘酮使地高辛稳态暴露增加79%。
- 按说明书推荐剂量联用时,胺碘酮使利伐沙班稳态暴露增加38%。
- 按说明书推荐剂量联用时,胺碘酮使苯妥英稳态暴露增加59%。
- 与单药治疗相比,地高辛、利伐沙班和苯妥英剂量分别降低40%、25%和45%可达到相似的稳态浓度。
关键数值与推荐
- 胺碘酮与地高辛联用时,建议地高辛剂量降低40%以达到与单药治疗相似的稳态浓度。
- 胺碘酮与利伐沙班联用时,建议利伐沙班剂量降低25%以达到与单药治疗相似的稳态浓度。
- 胺碘酮与苯妥英联用时,建议苯妥英剂量降低45%以达到与单药治疗相似的稳态浓度。
临床怎么用
- 临床在胺碘酮与地高辛、利伐沙班或苯妥英联用时,可参考模拟结果进行剂量调整以维持稳态暴露水平。
- 地高辛和苯妥英治疗窗窄,联用胺碘酮时需关注暴露增加导致的毒性风险。
- 利伐沙班联用胺碘酮时暴露增加可能增加出血风险,需评估并调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Amiodarone (AMI) is a potent inhibitor of Cytochrome P450 (CYP) 2C9 and P-glycoprotein (P-gp), as well as a weak inhibitor of CYP3A4. Concomitant administration of AMI with digoxin (DIG), rivaroxaban (RIV), or phenytoin (PHT) can significantly increase the exposure of the victim drugs. Elevated RIV exposure raises the risk of bleeding, whereas DIG and PHT have narrow therapeutic windows, potentially leading to severe toxicity when co-administered with AMI. PURPOSE: Physiologically based pharmacokinetic (PBPK) modeling was employed to simulate, validate, and predict the impact of drug-drug interactions (DDIs) between AMI and DIG, RIV, or PHT on the pharmacokinetics (PK) of victim drugs. The findings aim to provide evidence-based recommendations for optimizing combination therapy regimens. METHODS: PBPK models for AMI, RIV, and PHT were developed using PK-Sim, while the DIG model was adopted from previously published literature. DDI scenarios were simulated to assess exposure levels. Model performance was evaluated by comparing predicted plasma concentration-time (PCT) profiles and PK parameter values with clinical trial data from healthy subjects in previously published PK studies. Finally, dosing regimens for combination therapy were adjusted based on changes in exposure levels. RESULTS: According to model simulations, when the perpetrator drug AMI was co-administered with DIG, RIV, or PHT following label-recommended dosing regimens, the steady-state exposure of the victim drugs increased by 79%, 38%, and 59%, respectively. Compared to monotherapy, reducing the doses of DIG, RIV, and PHT by 40%, 25%, and 45%, respectively, achieved similar steady-state concentrations. CONCLUSIONS: We have successfully developed PBPK models for AMI, RIV, and PHT. These models effectively simulate the DDIs that occur when AMI is co-administered with DIG, RIV, or PHT, thereby providing guidance for dosing regimens in clinical combination therapies.
引用
- Chen Y, Liu Z, Li Y, et al. Drug-Drug Interactions and Combination Therapy Strategies of Amiodarone With Digoxin, Rivaroxaban, and Phenytoin Assessed by Physiologically Based Pharmacokinetic Modeling. Pharmacotherapy. 2025. PMID: 40798896. doi:10.1002/phar.70050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。